01.12.2021 | Can we warp-speed antibiotic development?
MEDCITY NEWS | We are living through the worst pandemic in a century, and infectious disease experts in the are sounding the alarm that drug-resistant bacteria will lead to another public health crisis. Misaligned market incentives related to development of antibiotics mean that necessary pharmacological innovations are deemed irrational investments. That means the burden is on the government to invest in these initiatives for the sake of public health. The constellation of US actors fighting antimicrobial resistance seek support for two new legislative fixes: the DISARM (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms) Act and the PASTEUR (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) Act. Together, the two support higher reimbursement rates and bulk purchasing of novel antibiotics.
01.08.2021 | Improving data sharing to increase the efficiency of antibiotic R&D
NATURE REVIEWS DRUG DISCOVERY | Greater investment is needed in antibiotic R&D, and more must be done to maximize the impact of such investments. More widespread data sharing, such as the recent joint data contribution from Merck and Kyorin to the Pew Charitable Trusts’ SPARK platform, has a key role. We need to spend more money on antibiotic R&D to address this challenge, but we can also spend smarter, by encouraging data sharing, especially from failed projects. This will help every antibiotic research team to stand on the shoulders of giants, instead of reinventing the wheel. Commentary authored by Kevin Outterson, Zak Zimmerman, Kevin Krause and Wes Kim.